Coherus Oncology (CHRS) Accounts Payables (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Accounts Payables data on file, last reported at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 71.95% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 71.95% YoY), and the FY2025 full-year result was $9.9 million, down 65.16% from the prior year.
• Accounts Payables climbed to $11.5 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $76.8 million in Q2 2024 to a low of $9.9 million in Q4 2025.
• A 5-year average of $27.9 million and a median of $24.9 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables plunged 78.3% in 2022 and surged 274.02% in 2023, its largest moves.
• Tracing CHRS's Accounts Payables over 5 years: stood at $11.5 million in 2022, then soared by 205.56% to $35.2 million in 2023, then declined by 19.2% to $28.5 million in 2024, then plunged by 65.16% to $9.9 million in 2025, then gained by 15.77% to $11.5 million in 2026.
• Business Quant data shows CHRS's Accounts Payables at $11.5 million in Q1 2026, $9.9 million in Q4 2025, and $24.9 million in Q3 2025.